Dry Age-Related Macular Degeneration Market Overview

The global Dry Age-Related Macular Degeneration market is estimated to be worth over USD 20.9 Bn in 2033 and is expected to grow at CAGR of 8.2% during the forecast period (2024-2033). Dry age-related macular degeneration (AMD) is an advanced eye disease marked by the decline of the macula, the primary part of the retina responsible for sharp, central vision. This condition generally develops gradually over through the years, leadingtogentle loss of vision in the affected eye. Dry AMD is the most prevalent form of AMD, accounting for approximately 85-90% of all AMD cases. The chieftrademark of dry AMD is the collection of drusen, small yellow deposits beneath the retina, which can resultin thinning and dysfunction of the macula. As dry AMD progresses, individuals are likely tosuffer symptoms such as blurred or distorted vision, trouble reading or determining faces, and mitigatedcolour perception. Whilst dry AMD usually progresses more gradually than its wet counterpart, it can still substantially impact visual function and quality of life, especially in advanced stages.

The global market for dry AMD embodiesdifferent sectors, comprisingmedical devices, pharmaceuticals, and diagnostic tools, focused at avoiding disease progression, administering symptoms, and improving patient outcomes. In current times, treatment alternatives for dry AMD are limited, with no approved therapies capable of halting or reversing disease progression. Nonetheless, there is continuing research and development emphasized on recognizing potential therapeutic targets and advanced treatment approaches. Pharmaceutical firms are exploring novel drug candidates targeting various pathways implicated in dry AMD pathogenesis, such as oxidative stress, inflammation, and complement activation. In addition to that, medical device companies are developing advanced retinal imaging technologies and artificial intelligence-based diagnostic tools to improve early detection and monitoring of dry AMD progression. Along with that, lifestyle interventions, comprising nutritional supplements, dietary modifications, and smoking cessation, are recommended to mitigate disease risk and slow progression in individuals at increased risk for dry AMD. As the global population ages and the prevalence of age-related eye diseases continues to rise, the market for dry AMD is estimated to grow, presenting opportunities for investment, innovation, and collaboration aimed at addressing the unmet medical needs of patients affected by this debilitating condition.

Figure 1. Dry Age-Related Macular Degeneration: Market Size

Get more details on this report - Request Free Sample

Key Market Insights &Current Market Landscape:

The global market for dry age-related macular degeneration (AMD) is shaped by numerous key market insights and continuous developments. With the aging population expanding across the world, dry AMD prevalence is growing, fueling demand for effective treatments and management strategies. Nevertheless, the current market panorama is marked by limited treatment alternatives, as there are no approved therapies capable of halting or reversing disease progression. Consequently, there is aurgent need for advanced therapeutic approaches targeting various aspects of dry AMD pathogenesis, such as inflammation, oxidative stress, and retinal degeneration. Significant developments in the market involve advancements in retinal imaging technologies and diagnostic tools aimed at improving early detection and monitoring of dry AMD progression. In addition to that, pharmaceutical companies are actively engaged in clinical research and development efforts to identify promising drug candidates and therapeutic targets for dry AMD. Collaborative initiatives between academia, industry, and regulatory agencies are fostering innovation and accelerating the translation of scientific discoveries into clinical applications. In spite of the existing challenges, the global dry AMD market presents opportunities for stakeholders to invest in research, innovation, and collaborative partnerships emphasized at addressing the unmet medical needs of patients affected by this chronic eye disease.

Market Dynamics

Market Drivers

Growing Aging Population

Age-related macular degeneration (AMD) affects one in eight people 60 years of age or older and is the most prevalent cause of irreversible blindness in older persons in developed countries. According to thorough estimates, 200 million people across the world are expected to have AMD, and by 2040, this number is estimated to rise to close to 300 million. By 2050, 5.4 million Americans are anticipated to be affected by rising patterns similar to this one.With aging being a leading risk factor for the development of AMD, the expanding elderly demographic across the worldassociates with a higher prevalence of the condition. As individuals age, the risk of witnessing age-associated changes in the macula, such as the accumulation of drusen and the thinning of retinal tissue, increases. As a consequence, there is a soaring pool of individuals at risk of developing dry AMD, fueling demand for diagnostic services, monitoring tools, and therapeutic interventions to administer the disease and preserve vision. The demographic shift towards an aging population not only intensifies the need for effective treatments but also underscores the prominence of early detection and preventive measures to minimize the impact of dry AMD on visual function and quality of life. Thus, as the older population persists to riseworldwide, the demand for advanced solutions addressing the challenges posed by dry AMD is estimated to surge, accelerating market growth and fostering advancements in the field of ophthalmology.

Market Restraints

With regard to numerous advantages of Dry Age-Related Macular Degeneration, the market faces several challenges due to the unique characteristics and requirements associated with them. Some of the key market challenges include:

• Limited Treatment Options: The dearth of approved therapies capable of halting or reversing disease progression poses a notable restraint on the global dry age-related macular degeneration market, confining treatment alternatives for patients and impeding market growth.
• High Cost of Research and Development: The increased cost and lengthy timelines related to research and development efforts focused at developing new therapies for dry age-related macular degeneration poses as a significant barrier to market entry for pharmaceutical companies, restraining innovation and investment in the field.

Market Opportunities

Presence of Several Pipeline Drugs

The presence of several pipeline drugs represents a significant market opportunity for the global dry age-related macular degeneration (AMD) market. Since there are currently no approved therapies capable of halting or reversing disease progression in dry AMD, the development of novel drug candidates provideshope for addressing this unmet medical need. Pharmaceutical firms are actively pursuing research and development efforts emphasized at determining promising therapeutic targets and innovative treatment approaches for dry AMD. These pipeline drugs target varied pathways implicated in AMD pathogenesis, such as oxidative stress, inflammation, and retinal degeneration. Clinical trials evaluating the safety and efficiency of these potential treatments are on the way, offering commitment for patients and healthcare providers alike. In addition to that, the introduction of novel therapies has the potential to revolutionize the treatment outlook for dry AMD, providing patients with more options for managing the disease and preserving vision. With advancements in drug development and promising results from clinical trials, the presence of pipeline drugs presents opportunities for market expansion, investment, and innovation in the global dry AMD market, ultimately enhancing outcomes for individuals affected by this debilitating eye condition.

Market Trends

• Increased Emphasis on Personalized Medicine: There is a soaring trend towards personalized medicine approaches in the global dry age-related macular degeneration (AMD) market, with an emphasize on tailoring treatments to individual patients' genetic profiles, disease subsets, and clinical characteristics to maximize therapeutic outcomes.
• Integration of Digital Health Solutions: Digital health solutions, comprising retinal imaging technologies, artificial intelligence-based diagnostic tools, and telemedicine platforms, are increasingly being integrated into the management of dry AMD, supporting early detection, remote monitoring, and personalized care delivery whilstimproving accessibility and efficiency in patient management.

Get more details on this report - Request Free Sample

Dry Age-Related Macular Degeneration Market: Key Segments

By Stages

• Early Age-Related Macular Degeneration
• Intermediate Age-Related Macular Degeneration
• Late Age-Related Macular Degeneration

By Age Group

• Above 75 Years
• Above 60 Years
• Above 40 Years

By Diagnosis and Treatment

• Treatment
• Diagnosis

By Route of Administration

• Oral
• Injectable

By End-User

• Hospitals and Clinics
• Diagnostic Centers
• Academic Research Institutes

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America 

Dry Age-Related Macular Degeneration Market: Regional Analysis

North America dominated the global market for dry age-related macular degeneration due to the rising number of people affected by the condition.

With the rise in diabeticpatients, ophthalmologic conditions are becoming more common. Retinal diseases like dry macular degeneration (AMD), retinal vein occlusion, and diabetic eye disease are becoming more common in the US.

Figure 4. Dry Age-Related Macular Degeneration Market: Distribution by Region

Get more details on this report - Request Free Sample

Leading Dry Age-Related Macular Degeneration Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the Dry Age-Related Macular Degenerationmarket, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the Dry Age-Related Macular Degenerationmarket are briefly discussed below. 

The report includes the list of players operating in the global Dry Age-Related Macular Degenerationmarket. Some of the key players include: 

• Alimera Sciences Inc
• Allergan Plc
• Belite Bio Inc
• Bausch Health (Valeant Pharmaceuticals)
• Eyestem Research Pvt Ltd
• IVERIC Bio
• Kubota Vision Inc
• Ocumension Therapeutics (Shanghai) Co. Ltd.
• RXi Pharmaceuticals Inc. (Phio Pharmaceuticals Corp)
• Santen Pharmaceuticals Inc
• Stealth Biotherapeutics Corp

Recent Developments in the Dry Age-Related Macular Degeneration Market

Several recent developments have taken place in the field of Dry Age-Related Macular Degeneration, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis chronologically.

• In August 2023, Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approved IZERVAY^™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction (p<0.01) in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: